Literature DB >> 27060559

Activation of oligodendroglial Stat3 is required for efficient remyelination.

Andrew J Steelman1, Yun Zhou2, Hisami Koito2, SunJa Kim1, H Ross Payne3, Q Richard Lu4, Jianrong Li5.   

Abstract

Multiple sclerosis is the most prevalent demyelinating disease of the central nervous system (CNS) and is histologically characterized by perivascular demyelination as well as neurodegeneration. While the degree of axonal damage is correlated with clinical disability, it is believed that remyelination can protect axons from degeneration and slow disease progression. Therefore, understanding the intricacies associated with myelination and remyelination may lead to therapeutics that can enhance the remyelination process and slow axon degeneration and loss of function. Ciliary neurotrophic factor (CNTF) family cytokines such as leukemia inhibitory factor (LIF) and interleukin 11 (IL-11) are known to promote oligodendrocyte maturation and remyelination in experimental models of demyelination. Because CNTF family member binding to the gp130 receptor results in activation of the JAK2/Stat3 pathway we investigated the necessity of oligodendroglial Stat3 in transducing the signal required for myelination and remyelination. We found that Stat3 activation in the CNS coincides with myelination during development. Stimulation of oligodendrocyte precursor cells (OPCs) with CNTF or LIF promoted OPC survival and final differentiation, which was completely abolished by pharmacologic blockade of Stat3 activation with JAK2 inhibitor. Similarly, genetic ablation of Stat3 in oligodendrocyte lineage cells prevented CNTF-induced OPC differentiation in culture. In vivo, while oligodendroglial Stat3 signaling appears to be dispensable for developmental CNS myelination, it is required for oligodendrocyte regeneration and efficient remyelination after toxin-induced focal demyelination in the adult brain. Our data suggest a critical function for oligodendroglial Stat3 signaling in myelin repair.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CNTF; Myelination; Oligodendrocyte maturation; Remyelination; Stat3 signaling

Mesh:

Substances:

Year:  2016        PMID: 27060559      PMCID: PMC4962532          DOI: 10.1016/j.nbd.2016.03.023

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  55 in total

1.  LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.

Authors:  Helmut Butzkueven; Jian-Guo Zhang; Merja Soilu-Hanninen; Hubertus Hochrein; Fiona Chionh; Kylie A Shipham; Ben Emery; Ann M Turnley; Steven Petratos; Matthias Ernst; Perry F Bartlett; Trevor J Kilpatrick
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

2.  Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice.

Authors:  W F Blakemore
Journal:  J Neurocytol       Date:  1972-12

3.  Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation.

Authors:  Qian Gao; Michael J Wolfgang; Susanne Neschen; Katsutaro Morino; Tamas L Horvath; Gerald I Shulman; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-22       Impact factor: 11.205

4.  Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients.

Authors:  Ranjan Dutta; Jennifer McDonough; Ansi Chang; Lakshman Swamy; Alan Siu; Grahame J Kidd; Richard Rudick; Karoly Mirnics; Bruce D Trapp
Journal:  Brain       Date:  2007-10       Impact factor: 13.501

5.  Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice.

Authors:  Zhengqi Lu; Xueqiang Hu; Cansheng Zhu; Dunjing Wang; Xueping Zheng; Quentin Liu
Journal:  J Neuroimmunol       Date:  2008-12-09       Impact factor: 3.478

Review 6.  Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.

Authors:  Etty N Benveniste; Yudong Liu; Braden C McFarland; Hongwei Qin
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

7.  Remyelination protects axons from demyelination-associated axon degeneration.

Authors:  K A Irvine; W F Blakemore
Journal:  Brain       Date:  2008-05-18       Impact factor: 13.501

8.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

9.  Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult.

Authors:  Ulrich Schweizer; Jennifer Gunnersen; Christoph Karch; Stefan Wiese; Bettina Holtmann; Kiyoshi Takeda; Shizuo Akira; Michael Sendtner
Journal:  J Cell Biol       Date:  2002-01-21       Impact factor: 10.539

10.  Adult-born SVZ progenitors receive transient synapses during remyelination in corpus callosum.

Authors:  Ainhoa Etxeberria; Jean-Marie Mangin; Adan Aguirre; Vittorio Gallo
Journal:  Nat Neurosci       Date:  2010-02-21       Impact factor: 24.884

View more
  17 in total

1.  Enhancing Remyelination through a Novel Opioid-Receptor Pathway.

Authors:  Jeremy C Borniger; Zoe C Hesp
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

Review 2.  Myelin status and oligodendrocyte lineage cells over time after spinal cord injury: What do we know and what still needs to be unwrapped?

Authors:  Nicole Pukos; Matthew T Goodus; Fatma R Sahinkaya; Dana M McTigue
Journal:  Glia       Date:  2019-08-24       Impact factor: 7.452

3.  High salt-induced activation and expression of inflammatory cytokines in cultured astrocytes.

Authors:  Zhezhi Deng; Yuge Wang; Li Zhou; Yilong Shan; Sha Tan; Wei Cai; Siyuan Liao; Lisheng Peng; Zhengqi Lu
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

4.  Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.

Authors:  SunJa Kim; Jacek Bielawski; Hyunmin Yang; Yu Kong; Beiyan Zhou; Jianrong Li
Journal:  Glia       Date:  2017-11-29       Impact factor: 7.452

5.  Alpha-lipoic acid mitigates toxic-induced demyelination in the corpus callosum by lessening of oxidative stress and stimulation of polydendrocytes proliferation.

Authors:  Nima Sanadgol; Fereshteh Golab; Hassan Askari; Fatemeh Moradi; Marziyeh Ajdary; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2017-10-12       Impact factor: 3.584

Review 6.  Regenerating CNS myelin - from mechanisms to experimental medicines.

Authors:  Robin J M Franklin; Charles Ffrench-Constant
Journal:  Nat Rev Neurosci       Date:  2017-11-16       Impact factor: 34.870

Review 7.  The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity.

Authors:  Josine E G Vaes; Myrna J V Brandt; Nikki Wanders; Manon J N L Benders; Caroline G M de Theije; Pierre Gressens; Cora H Nijboer
Journal:  Glia       Date:  2020-11-30       Impact factor: 7.452

8.  Sepantronium Bromide (YM155), A Small Molecule Survivin Inhibitor, Promotes Apoptosis by Induction of Oxidative Stress, Worsens the Behavioral Deficits and Develops an Early Model of Toxic Demyelination: In Vivo and In-Silico Study.

Authors:  Samaneh Reiszadeh-Jahromi; Mohammad-Reza Sepand; Samaneh Ramezani-Sefidar; Mohsen Shahlaei; Sajad Moradi; Meysam Yazdankhah; Nima Sanadgol
Journal:  Neurochem Res       Date:  2019-09-05       Impact factor: 4.414

Review 9.  Understanding the NG2 Glial Scar after Spinal Cord Injury.

Authors:  Amber R Hackett; Jae K Lee
Journal:  Front Neurol       Date:  2016-11-15       Impact factor: 4.003

10.  Neurogenic to Gliogenic Fate Transition Perturbed by Loss of HMGB2.

Authors:  Robert Bronstein; Jackson Kyle; Ariel B Abraham; Stella E Tsirka
Journal:  Front Mol Neurosci       Date:  2017-05-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.